Introduction
Dystonic symptoms (ICD-10 G24) such as torticollis and retrocollis are observed as abnormal, involuntary and sustained contractions of cervical muscles. As an extrapyramidal, hyperkinetic movement disorder the main focus of dysfunction is located in the so called cortico-striatal-pallidalthalamic-cortical (CSPTC) circuit (Fig. 1) [1], [2] . However, the pathophysiology of primary cervical dystonia (CD) is not fully understood yet, leading to only symptomatic treatments in clinical practice, such as botulinum toxin injections often associated with highly impaired motility of the patient [3] . Deep brain stimulation of CSPTC structures was proven to alleviate dystonic symptoms [2] . Besides these established methods, vagus nerve stimulation may be an asset in treating such movement disorders, provided the corresponding encouraging evidence in the invasive stimulation of the left cervical vagus nerve [4] . In order to avoid the drawback of highly invasive surgical procedures, punctual auricular vagus nerve stimulation (AVNS) may be an effective treatment [5] . This is supported by brain activation studies for transcutaneous AVNS [6] as well as by AVNS-based alleviation of symptoms in Parkinson's disease (unpublished data).
Methods
Two major signal transduction pathways may be involved in modulating the symptoms of CD (torticollis and retro- . Istimulation region; II -affected muscles; III -projection from the auricle to brainstem structures with direct feedback to the considered muscles; IV -projections of the brainstem to the cortico-striatal-pallidal-thalamiccortical circuit (CSPTC). NTS -nucleus tractus solitarii; NSNT -nucleus spinalis nervi trigemini; FR -formation reticularis; PB -parabrachial nucleus; NA -nucleus ambiguus; SNc,r -substantia nigra compacta, reticularis; GPi,eglobulus pallidus internus, externus; STN -sub-thalamic nucleus; inh. -inhibition; ex. -excitation.
collis). The corresponding symptoms include the involuntary activity of cervical muscles and especially of the musculus trapezius pars descendes (Fig. 1, see II) . The stimulation of vagal afferents (Fig. 1, I ) in the auricle is forwarded via the ganglion jugulare to the two sensory brainstem nuclei of the vagus nerve, i.e. the nucleus tractus solitarii (NTS) and the nucleus spinalis nervi trigemini (NSNT) [8] . A possible direct feedback to the musculus trapezius ( Fig. 1, III ) may be established via afferent projections from the NSNT to the nucleus ambiguus [1] . A second pathway (Fig. 1, IV) is build by projections of the formatio reticularis (FR) and the parabrachial nucleus to CSPTC, cerebellum and midbrain structures. This pathway modulates the complex control loops therein and thus the function of the motor cortex [1], [9] . Finally, pyramidal (gyrus praecentralis) and extrapyramidal (CSPTC, midbrain, FR) efferents are send to the muscles. The minimally-invasive AVNS is mediated via a small, wearable stimulation device P-Stim (Biegler GmbH, Austria). The P-Stim stimulates three vagally innervated regions of the auricle via inserted needles. The stimulation patterns comprise mono-phasic voltage impulses with changing polarity (Fig. 2a) . The stimulation rate is 1Hz, the impulse amplitude 4V, the impulse duration 1ms, and the on/off cycle is 3/3 hours. AVNS was applied for about one month on one female patient (49 years) who has suffered from CD for about three years and was resistant to any other therapy. For controlling aims, muscle activity at the left and right musculus trapezius was assessed after this AVNS therapy via electromyography (EMG) using a MP36 acquisition system (BIOPAC Systems Inc., USA).
Results
Preliminary outcome of the AVNS therapy showed significant subjective improvement in motility of the patient with CD. A typical EMG is shown in Fig. 2b with residual and non-symmetric contractions of the left and right musculus trapezius. However, our experimental evidence and the discussed transduction pathways (Fig. 1) indicate that therapeutic effects are subjected to significant neural plasticity in the brain. Likewise, the brain adapts to almost non-varying stimulation patterns, which disadvantageously diminishes therapeutic effects over extended periods of time.
Discussion
The presented investigations give novel evidence that AVNS is a possible alternative treatment for CD. However, we expect that adopted stimulation patterns and their variability in the course of the stimulation may even overcome adaptation processes in the brain and thus may significantly fortify therapeutic effects. Initial stimulation amplitude should be appropriate to produce comfortable, tingling sensation and thus to excite (only) thick afferent vagal nerve endings. On the other hand, varying stimulation frequency and/or pulse width can be expected to overcome adaptation processes and to maintain therapeutic effects in CD during long-term stimulation. Future studies will involve AVNS applications in CD (or other extrapyramidal movement disorders) with the proposed dynamics of the stimulation patterns, aimed at balanced and reduced non-symmetric muscle contractions. 
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